Barr Enjuvia Hormone Therapy To Launch After Approval Of More Doses
Executive Summary
Barr plans to launch Enjuvia by early 2005 when three additional strengths of the hormone therapy product are expected to become available, the company said
You may also be interested in...
Barr Kicks Off Enjuvia Detailing Two Years After First Approval
Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.
Barr Kicks Off Enjuvia Detailing Two Years After First Approval
Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.
Barr’s Bijuva Estrogen Cream Is “Not Approvable” At FDA
The agency will require additional clinical evidence pertaining to an unmet endpoint, Barr says. Two of three endpoints for the synthetic conjugated estrogens cream were met during clinical studies; the third was modified at FDA’s guidance after the trials began, the company says.